Thymosin Alpha-1: Immune-Modulating Thymic Peptide, Mechanism, Research, and Dosing Context

Thymosin alpha 1 (Tα1) is a 28-amino-acid peptide originally isolated from thymus tissue and studied for its role in regulating the immune system. Its synthetic form, thymalfasin, is approved in a number of countries outside the United States under the brand name Zadaxin, most prominently as a treatment for chronic viral hepatitis and as an immune adjunct. It is not an FDA-approved drug in the US. Among the peptides discussed in integrative and longevity practice, thymosin alpha-1 is unusual in having a regulatory approval history abroad and a body of human clinical research behind it. This page covers what thymosin alpha 1 is, how it is thought to work, what the evidence supports, how dosing is framed, and where it stands with the FDA today.

Thymosin alpha-1 is frequently confused with thymosin beta-4 and its fragment TB-500. Despite the shared name, they are different molecules with different biology: thymosin alpha-1 is an immune modulator, while the beta-thymosins are best known for actin regulation and tissue repair.

What Is Thymosin Alpha 1?

Origin in the Thymus

The thymus is the organ where T lymphocytes mature. Beginning in the 1960s, researchers extracted a mixture of thymic peptides — a preparation known as thymosin fraction 5 — and found that it influenced immune function in laboratory models. Thymosin alpha-1 was later identified as one of the active components of that mixture and characterized as a defined 28-amino-acid sequence. The synthetic peptide used clinically is chemically identical to the naturally occurring form and carries an acetylated N-terminus.

Thymosin Alpha-1 vs the Beta-Thymosins

The "thymosin" name covers peptides that were grouped by where they were first found rather than by what they do.

How Thymosin Alpha-1 Works

Innate Immune Signaling

The best-characterized action of thymosin alpha-1 is on the innate immune system. Research has described it acting through toll-like receptors (TLRs) on dendritic cells and other antigen-presenting cells, influencing how those cells mature and what signals they send to the adaptive immune system. Dendritic cells are the bridge between detecting a threat and mounting a targeted T-cell response, so influencing them has downstream effects across immune function.

T-Cell Maturation and Function

Consistent with its thymic origin, thymosin alpha-1 has been studied for effects on T-lymphocyte maturation and differentiation. Laboratory and clinical research has reported shifts in T-cell populations and in cytokine profiles associated with cell-mediated immunity. The framing most often used is immune modulation rather than stimulation: the peptide appears to help restore immune responses that are impaired, rather than simply amplifying immune activity.

Why "Modulator" Matters Clinically

That distinction is important for patient selection. A compound that broadly stimulates the immune system would raise concerns in autoimmune disease and in transplant recipients. Thymosin alpha-1 is described as modulatory, but that does not make it neutral in those populations — immune-active therapies of any kind warrant caution where the immune system is already dysregulated or deliberately suppressed.

What the Research Shows

Chronic Viral Hepatitis

The largest body of human evidence for thymosin alpha-1 comes from chronic hepatitis B and hepatitis C, which is also the basis of most of its approvals abroad. Trials have examined it alone and in combination with antiviral therapy. Results have been mixed across studies, and antiviral drugs with stronger and more consistent efficacy have since become the standard of care in the US — which helps explain why thymosin alpha-1 never became an established therapy here.

Immune Adjunct Use

Thymosin alpha-1 has been studied as an adjunct in settings where immune function is compromised, including as a vaccine-response enhancer in populations with weaker responses, in severe infection and sepsis, and alongside cancer therapy. These studies vary widely in size, design, and quality. Some have reported favorable immune or clinical markers; few meet the standard of large, well-controlled trials that a US approval would require.

Integrative and Longevity Practice

In integrative medicine, thymosin alpha-1 is discussed in the context of immune resilience, recovery from chronic infection, and immunosenescence — the gradual decline of immune function with age. These uses extrapolate from the mechanism and from the clinical populations above. They are reasonable hypotheses, but they are not established indications, and patients should hear that framing plainly.

How to Weigh the Evidence

Thymosin Alpha 1 Dosing Context

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Thymosin alpha-1 is one of the few peptides in this category with an established labeled regimen — but that labeling exists outside the United States, for specific indications. Internationally, thymalfasin (Zadaxin) has been labeled for subcutaneous injection on a twice-weekly schedule in chronic hepatitis B, with courses measured in months. That regimen reflects one indication in one population and is not a US-approved dose.

For compounded use in the US, there is no FDA-labeled dose. Protocols are prescriber-determined and typically reflect:

• Route. Subcutaneous injection is standard, mirroring the approved international product.
• Schedule. Intermittent dosing (a few times per week) rather than daily is the pattern used in the labeled regimen and commonly carried into protocols.
• Course length. Defined courses with reassessment, rather than open-ended use.
• Indication. The rationale — post-infectious recovery, immune adjunct, or immune aging — shapes duration and monitoring.

Dose magnitudes should be set by the prescriber against the specific compounded preparation. For reconstitution arithmetic, see our peptide calculator.

Safety and Side Effects

Thymosin alpha-1 has a long record of use under its international approvals, and its reported tolerability has generally been favorable. Reported issues include:

• Local injection-site reactions (redness, discomfort)
• Occasional transient symptoms reported in clinical use

Caution points for prescribers:

• Immunosuppressed patients by design. Transplant recipients and others on intentional immunosuppression warrant particular caution with any immune-active therapy.
• Autoimmune disease. The modulatory framing is not a guarantee of safety where autoimmunity is active.
• Pregnancy and breastfeeding. Data are insufficient; avoid unless a specialist directs otherwise.
• Product quality. Where compounding is permitted, preparations should come from a licensed 503A pharmacy with a certificate of analysis. Research-chemical products carry identity and purity risks.

Regulatory Status

As of July 2026, our FDA peptide status tracker lists thymosin alpha-1 in Category 1 — under evaluation, noting that it is approved internationally as Zadaxin. Category 1 is the interim category under which FDA does not currently intend to take action against 503A compounding with the substance, subject to the other 503A conditions, while it completes its review; it is not a final determination, and categories change. Check the tracker for current status before building a protocol around it.

This is a different position from the tissue-repair peptides discussed on our peptides for healing hub: FDA's briefing documents for the July 2026 PCAC meeting proposed not adding BPC-157 or TB-500 to the 503A Bulks List.

Athletes subject to anti-doping rules should confirm thymosin alpha-1's status with their governing body before any use.

Where Thymosin Alpha-1 Fits

Thymosin alpha-1 sits apart from the repair peptides it is often grouped with. BPC-157 and TB-500 are discussed for tissue healing; thymosin alpha-1 is discussed for the immune system that underlies recovery from illness. Our immune support overview covers the wider category, and practices evaluating a formulary can review the immune and gut health product connections.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is thymosin alpha 1 used for?

Thymosin alpha-1 is studied as an immune modulator. Its approvals outside the US (as thymalfasin, brand name Zadaxin) center on chronic viral hepatitis and use as an immune adjunct. In integrative practice it is discussed for immune resilience and immune aging, which are extrapolations rather than established indications.

Is thymosin alpha-1 the same as TB-500?

No. TB-500 is a synthetic fragment of thymosin beta-4, a different protein involved in actin regulation and tissue repair. Thymosin alpha-1 is a separate 28-amino-acid peptide with immune-modulating activity.

Is thymosin alpha 1 FDA-approved?

Not in the United States. It is approved in a number of other countries as thymalfasin. On the FDA tracker it is listed in Category 1 (under evaluation) for 503A compounding as of July 2026.

How is thymosin alpha-1 dosed?

There is no US-labeled dose. The international labeled regimen for chronic hepatitis B uses subcutaneous injection twice weekly over a course of months. Compounded protocols in the US are prescriber-determined and generally follow an intermittent subcutaneous schedule with a defined course length.

What are the side effects of thymosin alpha-1?

Reported tolerability has generally been favorable, with local injection-site reactions the most commonly described issue. Caution is warranted in transplant recipients, patients with active autoimmune disease, and during pregnancy.

Can thymosin alpha-1 be compounded?

As of July 2026 it is listed in Category 1, the interim category under which FDA does not currently intend to take action against 503A compounding with the substance, subject to the other 503A conditions, while its review continues. Confirm the current category with the compounding partner before prescribing. That status can change; check the tracker and confirm availability with the compounding partner.